SubsidieMeestersRevolutionising the diagnosis of multiple Sclerosis with the first bioinformatic diagnostic kit that allows early detection with a simple blood test
ALA DIAGNOSTICS aims to revolutionize multiple sclerosis diagnosis with a fast, non-invasive blood test using a patented biomarker, reducing misdiagnoses and improving patient outcomes.
Projectdetails
Introduction
Multiple Sclerosis affects around 700,000 people in Europe and 2.8 million worldwide. It is the most common chronic neurological disease in young adults in developed countries and the main cause of disability after traffic accidents.
Current Diagnosis Process
The current diagnosis process takes one year (on average), which makes pharmacological treatment start late, producing irreversible damage in patients and a worse prognosis.
Misdiagnosis and Healthcare Costs
Combined with the high rate of misdiagnoses (20%), this leads to a healthcare cost of around €20 billion every year.
ALA DIAGNOSTICS Solution
ALA DIAGNOSTICS is revolutionising MS diagnosis with the first MS diagnostic kit, based on our patented recombinant protein.
Key Features
This protein is the only specific and clinically validated biomarker that exists for the diagnosis of MS in blood. Our diagnostic test is:
- Fast
- Easy
- Cheap
- Non-invasive
- Suitable for early diagnosis of MS
- Easy to integrate into daily clinical routine
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.407.525 |
| Totale projectbegroting | € 2.010.750 |
Tijdlijn
| Startdatum | 1-2-2023 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ALA DIAGNOSTICS SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Transforming Molecular Diagnostics through NanoTechnologyAltratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Disruptive and high accuracy test for early colorectal cancer detection in bloodAMADIX aims to enhance early colorectal cancer detection through a novel blood test, PreveCol, integrating advanced biomarkers and AI-driven risk prediction, targeting commercialization by 2032. | EIC Accelerator | € 2.497.568 | 2022 | Details |
Pioneering diagnostics in dermatology and cancerDermagnostix aims to enhance dermatological diagnostics with a rapid, automated platform for precise molecular testing, reducing misdiagnoses and improving patient care. | EIC Accelerator | € 2.499.000 | 2022 | Details |
Revolutionising allergies diagnostics with the next generation of ultra-sensitive highly multiplexed diagnostic tests based on micro-pearlsNexdot is developing a groundbreaking diagnostic test using fluorescent µpearls to simultaneously assay IgE for 500+ allergens from a single drop of blood, significantly reducing diagnostic time and costs. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanningProSCAN aims to clinically validate a non-invasive liquid biopsy test for early-stage prostate cancer detection, potentially reducing unnecessary biopsies and associated costs significantly. | EIC Accelerator | € 1.987.387 | 2021 | Details |
Transforming Molecular Diagnostics through NanoTechnology
Altratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification.
Disruptive and high accuracy test for early colorectal cancer detection in blood
AMADIX aims to enhance early colorectal cancer detection through a novel blood test, PreveCol, integrating advanced biomarkers and AI-driven risk prediction, targeting commercialization by 2032.
Pioneering diagnostics in dermatology and cancer
Dermagnostix aims to enhance dermatological diagnostics with a rapid, automated platform for precise molecular testing, reducing misdiagnoses and improving patient care.
Revolutionising allergies diagnostics with the next generation of ultra-sensitive highly multiplexed diagnostic tests based on micro-pearls
Nexdot is developing a groundbreaking diagnostic test using fluorescent µpearls to simultaneously assay IgE for 500+ allergens from a single drop of blood, significantly reducing diagnostic time and costs.
Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanning
ProSCAN aims to clinically validate a non-invasive liquid biopsy test for early-stage prostate cancer detection, potentially reducing unnecessary biopsies and associated costs significantly.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
SLIMS: Scherpe Laesie Identificatie in Multiple ScleroseHet SLIMS platform ontwikkelt innovatieve methoden voor vroege MS-diagnose en verbeterde behandeling, ter verhoging van de levenskwaliteit. | Mkb-innovati... | € 171.500 | 2020 | Details |
DiaPro-MSHet project ontwikkelt de DiaPro MS-app om op basis van een geïntegreerd moleculair landschap betere diagnostiek en prognose voor MS-patiënten mogelijk te maken. | Mkb-innovati... | € 155.531 | 2015 | Details |
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s diseaseADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Fingerprinting Single Protein Molecules for Biomarker Assisted Precision MedicineSM-ProTrack aims to develop a low-cost, highly sensitive single-molecule sensing technology for detecting AMD biomarkers in small clinical samples, enhancing diagnostic capabilities and commercialization potential. | ERC Proof of... | € 150.000 | 2024 | Details |
Fast and simple biomarker detection by computational microscopyWe developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics. | ERC Proof of... | € 150.000 | 2024 | Details |
SLIMS: Scherpe Laesie Identificatie in Multiple Sclerose
Het SLIMS platform ontwikkelt innovatieve methoden voor vroege MS-diagnose en verbeterde behandeling, ter verhoging van de levenskwaliteit.
DiaPro-MS
Het project ontwikkelt de DiaPro MS-app om op basis van een geïntegreerd moleculair landschap betere diagnostiek en prognose voor MS-patiënten mogelijk te maken.
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease
ADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients.
Fingerprinting Single Protein Molecules for Biomarker Assisted Precision Medicine
SM-ProTrack aims to develop a low-cost, highly sensitive single-molecule sensing technology for detecting AMD biomarkers in small clinical samples, enhancing diagnostic capabilities and commercialization potential.
Fast and simple biomarker detection by computational microscopy
We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.